Egyptian Journal of Medical Human Genetics

Table 2 The relation between the c-MYC amplification and other clinical features and haematological parameters

From: The study of the impact of additional chromosomal aberrations and c-MYC and BCR::ABL1 genes amplification on CML patient’s characteristics: relation to haematological parameters and patient outcome

		c-MYC amplification		Test value	P value
		Negative	c-MYC amplification
		No. = 43	No. = 6
Age	Mean ± SD	46.7 ± 15.2	47.3 ± 13.5	− 0.083•	0.934
Age	Range	20–75	28–61	− 0.083•	0.934
Sex	Female	24 (55.8%)	2 (33.3%)	1.068*	0.301
Sex	Male	19 (44.2%)	4 (66.7%)	1.068*	0.301
Spleen	Moderate	17 (39.5%)	1 (16.7%)	1.185*	0.276
Spleen	Huge	26 (60.5%)	5 (83.3%)	1.185*	0.276
TLC	Median (IQR)	105 (51–200)	76 (48–91)	− 1.175 ≠	0.240
TLC	Range	29–283	33–116	− 1.175 ≠	0.240
Hb	Mean ± SD	8.7 ± 1.3	7.9 ± 0.8	1.315•	0.195
Hb	Range	6.3–11.1	7.1–9.6	1.315•	0.195
Plat	Median (IQR)	456 (92–550)	89 (63–93)	− 2.013 ≠	0.044
Plat	Range	34–900	45–498	− 2.013 ≠	0.044
PB blasts	Median (IQR)	4 (3–10)	15 (8–20)	− 2.180 ≠	0.029
PB blasts	Range	1–25	3–36	− 2.180 ≠	0.029
BM blasts	Median (IQR)	8 (6–15)	25 (16–51)	− 2.653 ≠	0.008
BM blasts	Range	5–61	9 – 51	− 2.653 ≠	0.008

P value > 0.05: Nonsignificant; P value < 0.05: Significant; P value < 0.01: Highly significant
^*: Chi-square test; •: Independent t test; ≠ : Mann–Whitney test. TLC: total leucocytic count; Hb: haemoglobin; Plat: platelet; PB blast: peripheral blood blast; BM blasts: bone marrow blasts; Sig: significancy; NS: nonsignificant; S: significant

Back to article page